Sutro Biopharma, Inc. (STRO) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Sutro Biopharma reported revenue of $102.5M, up 65.2% from $62.0M the year before. Net income was -$191.1M (a -186.5% net margin), or -$22.49 per diluted share. Operating margin was -154.5%. Operating activities generated -$177.2M of cash. At fiscal year end, Sutro Biopharma held $173.8M in total assets against $306.3M in total liabilities, including $58.1M of cash and equivalents.
Open the full interactive Sutro Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Sutro Biopharma Key Stats
| Share Price | $11.01 |
|---|---|
| Market Cap | $182.5M |
| Revenue YoY Growth | +65.2% |
| 52-Week Range | $7.30 – $40.91 |
| Shares Outstanding | 16.6 million (basic, 2026 Q2) |
Sutro Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $42.7M | $61.9M | $67.8M | $153.7M | $62.0M | $102.5M |
| Operating Income | -$71.1M | -$98.5M | -$128.9M | -$89.3M | -$238.5M | -$158.4M |
| Pre-Tax Income | -$32.0M | -$105.5M | -$116.7M | -$88.6M | -$225.1M | -$191.2M |
| Income Tax | $100,000 | $0 | $2.5M | $18.2M | $2.4M | -$93,000 |
| Net Income | -$32.1M | -$105.5M | -$119.2M | -$106.8M | -$227.5M | -$191.1M |
| Diluted EPS | -$14.80 | -$22.90 | -$23.50 | -$17.80 | -$29.60 | -$22.49 |
Sutro Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.7M | $11.6M | $14.5M | $9.8M |
| Net Income | -$56.9M | -$46.8M | -$38.5M | -$38.5M |
| Diluted EPS | -$6.70 | -$5.50 | -$2.94 | -$2.33 |
Sutro Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $206.2M | $30.4M | $47.3M | $69.3M | $190.3M | $58.1M |
| Current Assets | $378.2M | $218.5M | $353.2M | $421.5M | $343.3M | $150.9M |
| Total Assets | $394.1M | $341.4M | $406.9M | $470.7M | $387.2M | $173.8M |
| Current Liabilities | $29.6M | $41.7M | $66.5M | $93.7M | $131.9M | $75.1M |
| Total Long-Term Debt | $24.5M | $25.1M | $16.3M | $8.1M | — | — |
| Total Liabilities | $62.1M | $88.8M | $189.9M | $321.1M | $342.6M | $306.3M |
| Shareholders' Equity | $332.0M | $252.6M | $217.0M | $149.6M | $44.6M | -$132.5M |
Sutro Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$67.8M | -$81.7M | $3.5M | -$111.6M | -$191.5M | -$177.2M |
| Cash From Investing | $604,000 | -$97.3M | -$35.0M | -$3.9M | $218.5M | $45.0M |
| Cash From Financing | $269.2M | $3.3M | $48.3M | $137.6M | $94.1M | $44,000 |
Figures from Sutro Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sutro Biopharma financials page for every line item.
Sutro Biopharma Company Profile
| Ticker | STRO |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001382101 |
Frequently Asked Questions
What was Sutro Biopharma's revenue in fiscal 2025?
Sutro Biopharma (STRO) reported revenue of $102.5M for fiscal 2025.
What is Sutro Biopharma's annual revenue history?
Sutro Biopharma's annual revenue by fiscal year: 2020: $42.7M; 2021: $61.9M; 2022: $67.8M; 2023: $153.7M; 2024: $62.0M; 2025: $102.5M.
What was Sutro Biopharma's net income in fiscal 2025?
Sutro Biopharma reported net income of -$191.1M for fiscal 2025.
What was Sutro Biopharma's earnings per share (EPS) in fiscal 2025?
Sutro Biopharma's diluted EPS was -$22.49 for fiscal 2025 (adjusted for any later stock splits).
What was Sutro Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Sutro Biopharma reported revenue of $9.8M.
How many shares of Sutro Biopharma are outstanding?
Sutro Biopharma reported a weighted average of 16.6 million basic shares outstanding in 2026 Q2.
What is Sutro Biopharma's market cap?
Based on its latest closing price, Sutro Biopharma (STRO) has a market capitalization of about $182.5M.
When does Sutro Biopharma's fiscal year end?
Sutro Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Sutro Biopharma headquartered?
Sutro Biopharma lists its business address in South San Francisco, California in its SEC filings.
Sutro Biopharma Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →